Black checkmark with a sparkle and a curved line underneath on a white background.
Company

Acurx Pharmaceuticals, Inc.

Ticker
ACXP
Sector
Industry
Report date
November 12, 2026
Valye AI Score

100

Very high visibility
Recent developments
Recent developments summary

Recent developments include corporate governance changes, clinical trial progress, regulatory milestones, and financial activities.

Recent developments:
  • Acurx Pharmaceuticals amended its bylaws to reduce the stockholder quorum to 33⅓% [N1].
  • The company reported Q1 2026 earnings and discussed clinical progress in its earnings transcript [N2].
  • Acurx received FDA conditional acceptance and U.S. patents and trademark allowance for the Ibezapolstat brand name [N10].
  • The company advanced Phase 3 trials for CDI and initiated new clinical trials for RCDI [N10].
  • HC Wainwright & Co. reiterated a buy recommendation for Acurx Pharmaceuticals [N6].
  • Acurx won positive regulatory response from the EMA on Ibezapolstat use in children [N7].
Overview

Acurx Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company developing novel antibiotics, primarily focusing on Ibezapolstat for the treatment of Clostridioides difficile infection (CDI) and recurrent CDI (RCDI). The company is conducting Phase 3 clinical trials for CDI and has initiated new trials for RCDI. It has received conditional acceptance from the FDA and positive regulatory feedback from the EMA regarding pediatric use. The company funds its operations through equity offerings and maintains liquidity to support ongoing clinical development.

Executive summary

Financial figures (if any) are summarized from the latest available SEC filings and are provided for informational purposes only — not financial advice. Acurx Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company focused on developing Ibezapolstat for Clostridioides difficile infections. The company has advanced its lead drug candidate to Phase 3 trials and has received regulatory feedback from the FDA and EMA. As of September 30, 2026, the company reported a net loss of $2.58 million and maintains a strong liquidity position with over $14 million in cash and equivalents and a current ratio above 2.0 [S2]. Recent corporate governance changes include amending bylaws to reduce stockholder quorum [N1].

Scenarios for ACXP

Bull case model:

The company has progressed Ibezapolstat into late-stage clinical trials and secured regulatory feedback, including FDA conditional acceptance and EMA positive response for pediatric use. These milestones demonstrate clinical and regulatory progress. The company maintains liquidity to support ongoing development and has garnered analyst interest, indicating market recognition of its potential.

Bear case model:

Acurx Pharmaceuticals operates at a net loss with no current commercial products, relying on capital markets for funding. Clinical trial outcomes remain uncertain, and regulatory approvals are not guaranteed. The company faces risks typical of clinical-stage biopharmaceutical firms, including trial delays, regulatory setbacks, and competitive pressures.

Moat:

Acurx's moat is centered on its proprietary antibiotic candidate Ibezapolstat, which targets CDI, a significant healthcare-associated infection. The advancement to Phase 3 trials and regulatory interactions suggest a differentiated clinical development pathway. However, as a clinical-stage company without commercial products, its moat depends on successful trial outcomes and regulatory approvals, which remain uncertain.

Risks overview
Risks summary
The primary risks for Acurx Pharmaceuticals relate to clinical trial outcomes, regulatory approvals, and financial sustainability given its status as a clinical-stage biopharmaceutical company.
Risks details:

• Clinical Trial Risk: The success of Acurx depends on the outcomes of ongoing Phase 3 trials for Ibezapolstat. Negative or inconclusive results could materially impact the company's prospects.
• Regulatory Risk: Regulatory approvals from the FDA, EMA, and other agencies are required for commercialization. Delays or denials could affect the company's ability to bring products to market.
• Financial Risk: The company reports net losses and depends on equity offerings and capital markets to fund operations. Insufficient funding could hinder clinical development and operations.
• Market and Competitive Risk: The pharmaceutical market for CDI treatments is competitive, and alternative therapies could limit market adoption of Ibezapolstat.

FINAL FORECAST FOR ACXP

Final take one line
Acurx Pharmaceuticals is a clinical-stage biopharmaceutical company with high visibility into its drug development progress, regulatory interactions, and financial condition as of late 2026.
Final take 12 to 24 month view

Business trends: Advancement of Ibezapolstat into Phase 3 trials for CDI and initiation of new trials for RCDI, with regulatory feedback from FDA and EMA.
Execution milestones: Completion of Phase 3 clinical trials, regulatory approvals, and potential commercialization steps.
Key risks: Clinical trial outcomes, regulatory approval uncertainties, financial sustainability, and competitive market dynamics.

Valye AI Visibility Research Score

Very high visibility

Visibility score reflects the breadth and consistency of available disclosure across SEC filings, recent public reporting, and baseline business context (research-only; not investment advice).

100
LLM visibility overview
LLM Visibility known facts
  • Acurx Pharmaceuticals, Inc. is a publicly traded company on the Nasdaq Capital Market under the ticker ACXP [S1].
  • The company is incorporated in Delaware and headquartered in Staten Island, NY [S1].
  • Acurx is engaged in pharmaceutical development, with a focus on clinical trials for its drug candidate Ibezapolstat targeting Clostridioides difficile infection (CDI) and recurrent CDI (RCDI) [N2][N10].
  • The company has advanced Ibezapolstat to Phase 3 clinical trials for CDI and is conducting new clinical trials for RCDI [N10].
  • Acurx has received positive regulatory feedback, including conditional acceptance from the FDA and positive response from the European Medicines Agency (EMA) regarding Ibezapolstat use in children [N7][N10].
  • The company amended its bylaws to reduce the stockholder quorum to 33⅓% [N1].
  • Financial snapshot as of September 30, 2026, shows cash and equivalents of $14.46 million, current assets of $6.16 million (as of June 30, 2025), and current liabilities of $2.99 million, resulting in a current ratio of 2.06 and a cash ratio of 4.83 [S2].
  • Net income for the quarter ended September 30, 2026, was a loss of $2.58 million, with basic and diluted EPS of -$0.49 [S2].
  • The company has engaged in equity offerings and registered direct offerings in recent years to raise capital [S1][N10].
  • Acurx has received analyst coverage including a reiterated buy recommendation from HC Wainwright & Co. [N6].
  • The company has disclosed lobbying expenditures totaling $20,000 [N10].
Sources
Sources - Context summary

Generated 2026-11-12

Sources - Earning calls
Sources - Other context
Sources - SEC Filings
  • S1 | 2026-03-12 | 10-K
  • S2 | 2026-11-12 | 10-Q
Sources - News headlines
  • N1 | 2026-11-03 | www.nasdaq.com | Acurx Pharmaceuticals, Inc. Amends Bylaws to Reduce Stockholder Quorum to 33⅓% | https://www.nasdaq.com/articles/acurx-pharmaceuticals-inc-amends-bylaws-reduce-stockholder-quorum-33-1-3
  • N2 | 2026-05-12 | www.nasdaq.com | Acurx (ACXP) Q1 2026 Earnings Transcript | https://www.nasdaq.com/articles/acurx-acxp-q1-2026-earnings-transcript
  • N3 | 2026-03-19 | www.nasdaq.com | Can Acurx Pharmaceuticals (ACXP) Climb 226.3% to Reach the Level Wall Street Analysts Expect? | https://www.nasdaq.com/articles/can-acurx-pharmaceuticals-acxp-climb-2263-reach-level-wall-street-analysts-expect
  • N4 | 2026-03-17 | www.nasdaq.com | Is Acurx Pharmaceuticals (ACXP) Outperforming Other Medical Stocks This Year? | https://www.nasdaq.com/articles/acurx-pharmaceuticals-acxp-outperforming-other-medical-stocks-year
  • N5 | 2026-01-06 | www.nasdaq.com | Has Acurx Pharmaceuticals (ACXP) Outpaced Other Medical Stocks This Year? | https://www.nasdaq.com/articles/has-acurx-pharmaceuticals-acxp-outpaced-other-medical-stocks-year
  • N6 | 2025-10-01 | www.nasdaq.com | HC Wainwright & Co. Reiterates Acurx Pharmaceuticals (ACXP) Buy Recommendation | https://www.nasdaq.com/articles/hc-wainwright-co-reiterates-acurx-pharmaceuticals-acxp-buy-recommendation
  • N7 | 2025-09-30 | www.nasdaq.com | Acurx Pharmaceuticals Wins Positive Response From EMA On Ibezapolstat Use In Children | https://www.nasdaq.com/articles/acurx-pharmaceuticals-wins-positive-response-ema-ibezapolstat-use-children
  • N8 | 2025-06-18 | www.nasdaq.com | Are Medical Stocks Lagging Acurx Pharmaceuticals (ACXP) This Year? | https://www.nasdaq.com/articles/are-medical-stocks-lagging-acurx-pharmaceuticals-acxp-year
Important legal disclaimer

This material is for informational purposes only and does not constitute investment, financial, legal or tax advice, or an offer or solicitation to buy or sell any security. The Valye AI Score is a model-based estimate derived from public information and is subject to change without notice. No representation or warranty, express or implied, is made as to the accuracy, completeness or fairness of the information herein. Past performance is not indicative of future results. Investors should conduct their own research and consult a qualified financial adviser before making any investment decisions.

Blue logo with a stylized checkmark and star above the blue text 'VALYE' on a black background.

Generated by Valye SEC Pipeline Engine